Expectant management of veterans with early-stage prostate cancer

Cancer

Volumn 122, Issue 4, 2016, Pages 626-633

  Filson, Christopher P ^a,b,c   Shelton, Jeremy B ^a,d,e   Tan, Hung Jui ^a   Kwan, Lorna ^a   Skolarus, Ted A ^d,f   Saigal, Christopher S ^a,d,e   Litwin, Mark S ^a,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Rehab Res/Devmt Center   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

active surveillance; expectant management; prostate cancer; veterans' health; watchful waiting

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER RISK; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; EARLY CANCER; EXPECTANT MANAGEMENT; HEALTH CARE DISPARITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; REGIONALIZATION; VETERAN; BLOOD; CANCER GRADING; CANCER STAGING; CLINICAL PRACTICE; COHORT ANALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; RURAL POPULATION; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; URBAN POPULATION; UTILIZATION; WATCHFUL WAITING;

KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN;

AGE FACTORS; AGED; COHORT STUDIES; COMORBIDITY; HUMANS; KALLIKREINS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; PRACTICE PATTERNS, PHYSICIANS'; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RURAL POPULATION; UNITED STATES; URBAN POPULATION; VETERANS; WATCHFUL WAITING;

EID: 84959097757     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29785     Document Type: Article

References (27)

1. Hankey BF, Feuer EJ, Clegg LX, et al., Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999; 91: 1017-1024.
2. Wilt TJ, Brawer MK, Jones KM, et al., Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-213.
3. Filson CP, Marks LS, Litwin MS,. Expectant management for men with early stage prostate cancer. CA Cancer J Clin. 2015; 65: 264-282.
4. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
5. Sanda MG, Dunn RL, Michalski J, et al., Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
6. Baldwin LM, Andrilla CH, Porter MP, Rosenblatt RA, Patel S, Doescher MP,. Treatment of early stage prostate cancer among rural and urban patients. Cancer. 2013; 119: 3067-3075.
7. Makarov DV, Yu JB, Desai RA, Penson DF, Gross CP,. The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care. 2011; 49: 333-339.
8. Jacobs BL, Zhang Y, Schroeck FR, et al., Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013; 309: 2587-2595.
9. Chu S, Boxer R, Madison P, et al., Veterans Affairs telemedicine: bringing urologic care to remote clinics. Urology. 2015; 86: 255-261.
10. Whittle J, Conigliaro J, Good CB, Lofgren RP,. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med. 1993; 329: 621-627.
11. Goulet JL, Erdos J, Kancir S, et al., Measuring performance directly using the Veterans Health Administration electronic medical record: a comparison with external peer review. Med Care. 2007; 45: 73-79.
12. Rural Health Research Center. Rural-Urban Commuting Area Codes (RUCAs). http://depts.washington.edu/uwruca/. Accessed June 1, 2015.
13. D'Amico AV, Whittington R, Malkowicz SB, et al., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974.
14. Charlson M, Szatrowski TP, Peterson J, Gold J,. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47: 1245-1251.
15. Ritch CR, Graves AJ, Keegan KA, et al., Increasing use of observation among men at low risk for prostate cancer mortality. J Urol. 2014; 193: 801-806.
16. Cooperberg M, Carroll P,. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015; 314: 80-82.
17. Snyder CF, Frick KD, Blackford AL, et al., How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer. 2010; 116: 5391-5399.
18. Daskivich TJ, Fan KH, Koyama T, et al., Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013; 158: 709-717.
19. Cetnar JP, Hampton JM, Williamson AA, et al., Place of residence and primary treatment of prostate cancer: examining trends in rural and nonrural areas in Wisconsin. Urology. 2013; 81: 540-546.
20. Aizer AA, Paly JJ, Zietman AL, et al., Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012; 30: 3071-3076.
21. Ramsey SD, Zeliadt SB, Fedorenko CR, et al., Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011; 29: 3-9.
22. Davison BJ, Breckon E,. Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. Patient Educ Couns. 2012; 87: 369-374.
23. Hoffman KE, Niu J, Shen Y, et al., Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med. 2014; 174: 1450-1459.
24. Goldstein MK, Lavori P, Coleman R, Advani A, Hoffman B,. Improving adherence to guidelines for hypertension drug prescribing: cluster-randomized controlled trial of general versus patient-specific recommendations. Am J Manag Care. 2005; 11: 677-685.
25. Burks FN, Liu AB, Suh RS, et al., Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer. J Urol. 2012; 188: 2108-2113.
26. National Comprehensive Cancer Network. Active surveillance monitoring more stringent in updated NCCN guidelines for prostate cancer. http://www.nccn.org/about/news/newsinfo.aspx?NewsID=274. Accessed December 15, 2014.
27. Filson CP, Schroeck FR, Ye Z, Wei JT, Hollenbeck BK, Miller DC,. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer. J Urol. 2014; 192: 75-80.